Our TIME analysis exhibited similar immune cell infiltrations, immune-related gene transcripts, and ICIs response predictive scores and signatures, supporting a comparable clinical benefit from ICIs between the BRAF V600E and Non-V600E subgroups of NSCLC patients. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.